This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Derazantinib
- DrugBank Accession Number
- DB14889
- Background
Derazantinib is under investigation in clinical trial NCT03230318 (Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Derazantinib (DB14889)
- Weight
- Average: 468.576
Monoisotopic: 468.232539733 - Chemical Formula
- C29H29FN4O
- Synonyms
- Derazantinib
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Derazantinib dihydrochloride U6B7J0L31Q 1821329-75-2 Not applicable
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- N9B0H171MJ
- CAS number
- 1234356-69-4
- InChI Key
- KPJDVVCDVBFRMU-AREMUKBSSA-N
- InChI
- InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
- IUPAC Name
- (6R)-6-(2-fluorophenyl)-N-(3-{2-[(2-methoxyethyl)amino]ethyl}phenyl)-5H,6H-benzo[h]quinazolin-2-amine
- SMILES
- COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C4=CC=CC=C4C3=N2)=CC=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 59718644
- ChEMBL
- CHEMBL4297187
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Combined Hepatocellular-cholangiocarcinoma / Intrahepatic Cholangiocarcinoma 1 2 Recruiting Treatment Intrahepatic Cholangiocarcinoma 1 1 Completed Other Healthy Subjects (HS) 1 1, 2 Completed Treatment Solid Tumors 1 1, 2 Completed Treatment Urothelial Carcinoma 1 1, 2 Terminated Treatment Gastric Adenocarcinoma 1 Not Available Available Not Available Intrahepatic Cholangiocarcinoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00106 mg/mL ALOGPS logP 5.45 ALOGPS logP 6.13 Chemaxon logS -5.6 ALOGPS pKa (Strongest Acidic) 13.8 Chemaxon pKa (Strongest Basic) 9.53 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 59.07 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 138.11 m3·mol-1 Chemaxon Polarizability 51.26 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at May 20, 2019 14:33 / Updated at December 13, 2022 10:46